Vaccine prospects of killed but metabolically active leishmania against visceral leishmaniasis

Expert Review of Vaccines

Volumn 11, Issue 7, 2012, Pages 783-785

  Das, Amrita ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

killed but metabolically active; killed parasites; Leishmania infantum chagasi; leishmaniasis; vaccine

Indexed keywords

AMOTOSALEN; INACTIVATED VACCINE; LEISHMANIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; FEMALE; IMMUNE RESPONSE; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; ULTRAVIOLET A RADIATION; VACCINATION; VIRUS REPLICATION; VISCERAL LEISHMANIASIS;

EID: 84865441897     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.50     Document Type: Review

References (8)

1. Bhaumik SK, Singh MK, Karmakar S, De T. UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis. Glycoconj. J. 26(6), 663-673 (2009).
2. Handman E. Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 14(2), 229-243 (2001). (Pubitemid 32294669)
3. Daneshvar H, Coombs GH, Hagan P, Phillips RS. Leishmania mexicana and Leishmania major: Attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 187(10), 1662-1668 (2003). (Pubitemid 36578973)
4. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73(10), 6372-6382 (2005). (Pubitemid 41368798)
5. Silvestre R, Cordeiro-da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J. Immunol. 179(5), 3161-3170 (2007).
6. Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J. Immunol. 183(3), 1813-1820 (2009).
7. Birnbaum R, Haskell J, Vanchinathan V et al. Killed but metabolically active Leishmania as a novel whole-cell vaccine for visceral leishmaniasis. Clin. Vaccine Immunol. 19(4), 490-498 (2012).
8. Mizbani A, Taheri T, Zahedifard F et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1), 53-62 (2009).